All In Biotech

Drug Trial Radar · NCT06267846

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Mar 20, 2024

Primary completion

Jul 25, 2025

Study completion Sep 11, 2025

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).

Conditions

  • Major Depressive Disorder

Interventions

  • NBI-1070770Drug

    Suspension for oral administration

  • PlaceboDrug

    Suspension for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score from Baseline to Day 5Time frame: Baseline, Day 5

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Little Rock, Arkansas

  • Neurocrine Clinical Site

    Rogers, Arkansas

  • Neurocrine Clinical Site

    Lemon Grove, California

  • Neurocrine Clinical Site

    Long Beach, California

  • Neurocrine Clinical Site

    Hollywood, Florida

  • Neurocrine Clinical Site

    Maitland, Florida

  • Neurocrine Clinical Site

    Decatur, Georgia

  • Neurocrine Clinical Site

    Savannah, Georgia

  • Neurocrine Clinical Site

    Gaithersburg, Maryland

  • Neurocrine Clinical Site

    Dayton, Ohio

  • Neurocrine Clinical Site

    North Canton, Ohio

  • Neurocrine Clinical Site

    Houston, Texas

  • Neurocrine Clinical Site

    Richardson, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.